Lindbrook Capital’s ImmunityBio IBRX Stock Holding History

Lindbrook Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$2.22K	Sell	737 -263	-26%	-$797	﹤0.01%	2249
2024 Q4	$2.56K	Hold	1,000	–	–	﹤0.01%	2228
2024 Q3	$3.72K	Buy	+1,000	New	+$4.63K	﹤0.01%	2133
2023 Q1	–	Sell	-1,000	Closed	-$5.07K	–	2842
2022 Q4	$5.07K	Buy	+1,000	New	+$5.49K	﹤0.01%	1818
2022 Q2	–	Sell	-1,000	Closed	-$6K	–	2603
2022 Q1	$6K	Hold	1,000	–	–	﹤0.01%	1527
2021 Q4	$6K	Hold	1,000	–	–	﹤0.01%	1442
2021 Q3	$10K	Hold	1,000	–	–	﹤0.01%	988
2021 Q2	$14K	Hold	1,000	–	–	﹤0.01%	913
2021 Q1	$24K	Hold	1,000	–	–	0.01%	687
2020 Q4	$13K	Hold	1,000	–	–	﹤0.01%	811
2020 Q3	$7K	Hold	1,000	–	–	﹤0.01%	961
2020 Q2	$12K	Buy	+1,000	New	+$5.65K	﹤0.01%	774

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lindbrook Capital's IBRX Position: Q1 2025 in Review

Lindbrook Capital reduced its ImmunityBio (IBRX) stake by 26% in Q1 2025, selling an estimated $797 and leaving 737 shares worth $2.22K. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

Lindbrook Capital first reported a position in IBRX in Q2 2020 and has held it in 12 quarters since. The position peaked at $24K in Q1 2021. 211 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

Lindbrook Capital held 737 shares of ImmunityBio worth $2.22K as of Q1 2025.
Lindbrook Capital sold 263 ImmunityBio shares in Q1 2025, an estimated $797.
ImmunityBio made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2249 holding.
Lindbrook Capital first reported a position in ImmunityBio in Q2 2020 and has held it in 12 quarters since.
Lindbrook Capital's ImmunityBio position peaked at $24K in Q1 2021.
211 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.